This quantitative ctDNA test measuring levels of methylated BCAT1/IKZF1 DNA in blood reflects tumor burden at diagnosis and provides a baseline for demonstrating response to differing therapeutic approaches for colon and rectal cancer. Here, IKZF1 is linked to rectal cancer.